The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-β-lactamase

Bo Ma1,3, Chao Fang1,3, Linshan Lu2,3, Mingzhi Wang1, Xiaoyan Xue1, Ying Zhou1, Mingkai Li1, Yue Hu1, Xiaoxing Luo1 & Zheng Hou1

New Delhi metallo-β-lactamase-1 (NDM-1) is the most prevalent type of metallo-β-lactamase and hydrolyzes almost all clinically used β-lactam antibiotics. Here we show that the antimicrobial peptide thanatin disrupts the outer membrane of NDM-1-producing bacteria by competitively displacing divalent cations on the outer membrane and inducing the release of lipopolysaccharides. In addition, thanatin inhibits the enzymatic activity of NDM-1 by displacing zinc ions from the active site, and reverses carbapenem resistance in NDM-1-producing bacteria in vitro and in vivo. Thus, thanatin’s dual mechanism of action may be useful for combating infections caused by NDM-1-producing pathogens.
New Delhi metallo-β-lactamase-1 (NDM-1)-producing bacteria have been rapidly developing resistance to almost all antibiotics, including carbapenems1-2. The extensive horizontal transfer of blaNDM-1 among various types of Gram-negative strains, especially *Escherichia coli* (*E. coli*) and *Klebsiella pneumoniae* (*K. pneumoniae*), accelerates the severe global spread of the gene3-4. In addition, *blaNDM-1* intercalates into existing resistance genes and evolutionarily generates new mutants. Previous studies reported that the resistance gene *mcr-1* can coexist with *blaNDM-1* in *E. coli*, thereby severely worsening such situation5-8. Considering the ever-increasing, fast-spread and highly lethal NDM-1-producing strains, the development of new drugs is urgently needed to combat these pathogens.

The hydrolytic activity of NDM-1 depends on the binding of Zn$^{2+}$ ions to the active site, which activates nucleophilic H$_2$O and causes the cleavage of β-lactam rings9. Nevertheless, in the absence of Zn$^{2+}$ ions, the stability of NDM-1 decreases significantly, which adversely affects the accumulation of this enzyme in the bacterial periplasm9. The innate immune system responds to metallo-β-lactamase-producing bacteria by releasing metal-chelating proteins, which will cause the degradation of metallo-β-lactamases10,11. However, resistant bacteria anchor NDM-1 to the outer membrane (OM) to avoid chelation so that the hydrolytic efficacy can be preserved even under the condition of metal depletion9.

Thanatin is an inducible 21-residue insect peptide with a disulfide bond between Cys11 and Cys1812. Our previous studies revealed that thanatin exerts prominent antibacterial effects on extended-spectrum β-lactamase-producing *E. coli*13. However, whether thanatin is also effective against NDM-1-producing bacteria remains unclear. In the present study, we examined the antibacterial efficacy of thanatin on NDM-1-producing strains and found that it affects both bacterial viability and NDM-1 enzyme activity. Our results showed that thanatin has the property of competitive replacement of divalent cations from bacterial OM, leading to OM disruption. Remarkably, thanatin also acts as an antibiotic adjuvant even under low concentrations by displacing zinc ions from the active site of the NDM-1 enzyme to restore the susceptibility of NDM-1-producing pathogens to β-lactam antibiotics. The unique antibacterial mechanisms of thanatin provide a strategy for combating infections of NDM-1 pathogens.

**Results**

**Thanatin exerts bactericidal activity by disrupting OM integrity.** Seven clinically isolated NDM-1-producing strains and three reference strains were used to assess the in vitro antibacterial activity of thanatin. NDM-1 expression was verified in all seven clinically isolated strains (Supplementary Fig. 1). As predicted, thanatin exhibited potent inhibitory effect on the growth of all NDM-1-producing *E. coli* and *K. pneumoniae* strains at 0.4–3.2 μM of the minimum inhibitory concentration (MIC) values (Table 1), whereas these strains showed much lower susceptibilities to penicillin, cephalosporin, carbapenem, and quinolone antibiotics (Table 1, Supplementary Tables 1 and 2). The bactericidal kinetics study of thanatin at the MIC levels showed rapid bacterial reduction from 10$^8$ to 10$^2$ and less than 50 colony-forming units (CFU)/mL at 1 and 3 h, respectively (Fig. 1a, b, Supplementary Fig. 2). The OM integrity was damaged by thanatin in a time-dependent manner, and a distinct increase in the fluorescence intensity was observed 1 h post incubation (Fig. 1c).

The fluorescence intensity of propidium iodide (PI) increased ~2 h post incubation, indicating an increase in the inner membrane permeability of the bacteria (Fig. 1d). The scanning electron microscopy image showed that the number of *E. coli* cells with dramatic morphological changes gradually increased with increasing thanatin concentration; consequently, the cells exhibited aggravating corrugation on the surface (Fig. 1e).

| Strains                  | MICs                  | Thanatin (μg/mL) | Piperacillin (μg/mL) | Oxacillin (μg/mL) | Meropenem (μg/mL) | Imipenem (μg/mL) | Cefazidime (μg/mL) | Cefotaxime (μg/mL) |
|-------------------------|-----------------------|------------------|---------------------|------------------|------------------|------------------|-------------------|-------------------|
| *E. coli* ATCC25922     |                      | 4/1.6            | 2                   | 64               | <0.125           | <0.125           | <0.125            | <0.125            |
| *E. coli* ATCC35218     |                      | 1/0.4            | ≥256                | 256              | <0.125           | <0.125           | <0.125            | <0.125            |
| *K. pneumoniae* ATCC13883 |                    | 4/1.6            | 8                   | 64               | <0.125           | <0.125           | <0.125            | <0.125            |
| NDM-1 *E. coli* XJ141015 |                      | 2/0.8            | ≥256                | ≥256             | 64               | 16               | ≥256              | ≥256              |
| NDM-1 *E. coli* XJ141026 |                      | 2/0.8            | ≥256                | ≥256             | 64               | 16               | ≥256              | ≥256              |
| NDM-1 *E. coli* XJ141047 |                      | 2/0.8            | ≥256                | ≥256             | 64               | 32               | ≥256              | ≥256              |
| NDM-1 *K. pneumoniae* XJ155017 |                | 8/3.2            | ≥256                | ≥256             | ≥256             | ≥256             | ≥256              | ≥256              |
| NDM-1 *K. pneumoniae* XJ155018 |                | 8/3.2            | ≥256                | ≥256             | 128              | 128              | ≥256              | ≥256              |
| NDM-1 *K. pneumoniae* XJ155019 |                | 8/3.2            | ≥256                | ≥256             | 128              | 128              | ≥256              | ≥256              |

Thanatin damages the OM by promoting the release of divalent cations. Divalent cations, which link the negatively charged phosphate groups between lipopolysaccharides (LPS) molecules via ionic bridges, are crucial for the OM integrity of Gram-negative bacteria14. The replacement or chelation of divalent cations would disrupt OM integrity and permeabilize bacteria. The release of Ca$^{2+}$ and LPS was detected to further investigate the effects of thanatin on the OM of NDM-1-producing bacteria. NDM-1-producing *E. coli* XJ141026 showed an immediate release of Ca$^{2+}$ into the supernatant after incubation with thanatin at concentrations of 13 or 26 μM as early as 0.5 h post incubation (Fig. 2a). Thereafter, LPS was released at 3 h, indicating the gradual destruction of OM under the condition of divalent cation loss (Fig. 2b). Consistently, the bacterial loads of the thanatin-treated groups significantly decreased 3 h post incubation (Fig. 2c).

We then determined the release of Ca$^{2+}$ and LPS induced by thanatin from bacterial OM in a mouse pneumonia model infected with NDM-1-producing *E. coli* XJ141026 or *K. pneumoniae* XJ155017. The results showed that the LPS concentration in bronchoalveolar lavage fluid (BALF) increased...
significantly after treatment with thanatin for 1 h, whereas no significant difference was observed at 6 h (Fig. 2d, Supplementary Fig. 3a). The lack of increase in LPS release in BALF at 6 h may be associated with the decrease in the bacterial titers after thanatin treatment (Fig. 2e, Supplementary Fig. 3b). The survival rates were improved from 40 to 90% after treatment with 6 mg/kg thanatin in E. coli XJ141026-infected mice (Fig. 2f) and from 50 to 100% after treatment with 9 mg/kg thanatin in K. pneumoniae-infected mice (Supplementary Fig. 3c). The increasing survival rates caused by thanatin treatment were associated with reduced bacterial titers and restricted pneumonia aggravation in the lungs of the infected mice (Supplementary Figs. 3d, e and Supplementary Figs. 4a, b).

**Thanatin competitively replaces divalent cations from LPS.** To verify the mechanism of thanatin in promoting the release of LPS and Ca$^{2+}$, we investigated the relationship among divalent cations, LPS, and antibacterial activity of thanatin. Our results showed that thanatin-induced LPS release from NDM-1-producing E. coli XJ141026 was significantly reduced with increasing Ca$^{2+}$ concentrations (Fig. 3a). Meanwhile, the bactericidal efficacy of thanatin was inhibited by adding extra divalent ions into the systems (Fig. 3b). The MICs increased dramatically with increasing concentrations of Ca$^{2+}$ and Mg$^{2+}$ (Fig. 3c). Consistently, the chelation of the divalent cations by metal-chelating agent dipicolinic acid (DPA) and ethylenediaminetetraacetic acid (EDTA) facilitated the bactericidal activity of thanatin, that is, the MICs were decreased to 0.0625- and 0.1563-fold compared with that when thanatin alone was used (Fig. 3d). These results indicated that thanatin likely competitively replaces the divalent cations from OM to exert antibacterial activity. To acquire direct evidence, we examined the affinities of thanatin, Ca$^{2+}$, and Mg$^{2+}$ to LPS by isothermal titration calorimetry (ITC). The equilibrium dissociation constant ($K_d$) of thanatin to LPS was 1.09 ± 0.11 μM, whereas the values for Ca$^{2+}$ and Mg$^{2+}$ were
**Fig. 2** Thanatin promotes the release of Ca\(^{2+}\) and LPS from the OM. a–c Release of Ca\(^{2+}\) (a) and LPS (b) from thanatin-treated *E. coli* XJ141026 (3 × 10\(^{10}\) CFU/mL) was detected, and time-kill curves were monitored (c). d, e LPS levels (d) and bacterial loads (e) in the BALF of *E. coli* XJ141026-infected pneumonia mice were analyzed at 1 and 6 h after 6 mg/kg thanatin treatment (n = 6 per group). f Survival curves for the *E. coli* XJ141026 pneumonia model. BALB/c mice were intranasally infected with a sublethal dose of *E. coli* XJ141026 and treated with 6 mg/kg thanatin via intraperitoneal injection (n = 10 per group). All data are shown as the mean ± s.e.m. from at least three independent experiments. P-values were determined by two-way ANOVA (a–c), two-tailed unpaired t-test (d, e) or log-rank test (f). ns means not significant; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control or model. Source data are provided in Source Data file.

**Fig. 3** Thanatin replaces divalent cations from LPS. a, b Effects of Ca\(^{2+}\) on thanatin-induced LPS release from NDM-1-producing *E. coli* XJ141026 (a) and CFUs (b) after treatment with 13 or 26 μM thanatin. c, d Effect of the divalent cations Ca\(^{2+}\) or Mg\(^{2+}\) (c) or the metal-chelating agents DPA or EDTA (d) on the MIC of thanatin against NDM-1-producing *E. coli* XJ141026. e ITC thermograms for the binding of LPS to thanatin. The downward peaks indicate an exothermic process. All data are shown as the mean ± s.e.m. from three independent experiments. P-values were determined by two-way ANOVA (a, b). ns means not significant; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control (0 mM Ca\(^{2+}\)). Source data are provided in Source Data file.
Thanatin protects mice infected with NDM-1-producing *E. coli*. We examined the in vivo therapeutic effects of thanatin in a sepsis model induced by NDM-1-producing *E. coli* XJ141026. All septic mice died within 2 d post infection, whereas treatment with 1, 3, and 6 mg/kg thanatin markedly increased the survival rate from 0 to 30%, 70%, and 100%, respectively (Fig. 4a). Tissues were collected 24 h post infection to analyze bacterial CFUs after treatment. The results showed that the bacterial titers decreased with increasing thanatin dose (Fig. 4b). The therapeutic effects were confirmed by histological staining. We observed dramatic pathological changes in the model group, including large amounts of inflammatory cell infiltration, alveolar fusion, congestion in the spleen red pulp area, hepatic sinusoidal dilation and congestion (Supplementary Fig. 6). By contrast, the thanatin treatment rescued the pathological damages in a dose-dependent manner (Supplementary Fig. 6).

To examine the cell toxicity of thanatin, we used human umbilical vein endothelial cells (HUVECs), human pulmonary alveolar epithelial cells (HPAEpiCs), and mouse neuron cells. At the concentration of 200 μM, almost all thanatin-treated HPAEpiCs were alive, but only 73.8% of cells survived after colistin treatment (Supplementary Fig. 7a). Similarly, 82.9% of thanatin-treated HUVECs survived, but 60.5% of colistin-treated cells were alive at the same concentration of 200 μM (Supplementary Fig. 7b). These results indicated that thanatin had lower toxicity toward HPAEpiCs and HUVECs than colistin. Hoechst 33342 and PI staining assay results showed that no differences between the control and 50 μM thanatin-treated groups when incubated with mouse primary neuron cells (Supplementary Fig. 7c). This finding implied that thanatin exhibited high selectivity toward bacterial cell walls but not on mammalian cell membranes.

**Thanatin inactivates NDM-1 by displacing zinc ions.** The NDM-1 protein is anchored to the OM of Gram-negative bacteria and is involved in enzymatic reaction in the periplasmic space. Both thanatin and colistin damage the OM integrity, causing the release of NDM-1 into the solution in a time- and concentration-dependent manner (Fig. 5a, Supplementary Figs. 8a, b and 13).

**Fig. 4** Thanatin protects NDM-1-producing *E. coli*-infected mice. a Survival curves for the *E. coli* XJ141026 sepsis model. BALB/c mice were intraperitoneally administered with a lethal dose of *E. coli* XJ141026 and treated with three doses of thanatin via intraperitoneal injection (*n* = 10 per group). b Bacterial loads in the blood, lungs, livers, and spleens of thanatin-treated *E. coli* XJ141026-infected mice were determined 24 h after infection (*n* = 6 per group). *P*-values were determined by log-rank test (a) or one-way ANOVA with post-Bonferroni’s comparison test (b). **P* < 0.01, ***P* < 0.001 vs. model. Source data are provided in Source Data file.

Meanwhile, the levels of NDM-1 decreased in the thanatin- and colistin-treated *E. coli* XJ141026 cell precipitates (Supplementary Figs. 8b, c and 13). As a result, the hydrolysis rates of the precipitates decreased with increasing thanatin or colistin concentration due to the release of NDM-1 into the supernatant (Supplementary Figs. 9a, b). We speculated that high NDM-1 levels in the supernatant were related to the efficient hydrolytic activity. Unexpectedly, the hydrolysis of the supernatant to imipenem decreased with increasing thanatin concentration (Fig. 5b). By contrast, treatment with high colistin concentration led to strong hydrolytic activity to imipenem (Supplementary Fig. 8f).

In addition to membrane permeabilization, thanatin likely interacted with NDM-1 and inhibited its hydrolytic activity. To determine the direct interaction between NDM-1 and thanatin, microscale thermophoresis (MST) was used to detect the binding affinities of apo-NDM-1 to Zn$^{2+}$, thanatin and colistin. We measured a $K_d$ of ~0.71 ± 0.06 μM for the interaction between NDM-1 and thanatin (Fig. 5c). Weak affinities to NDM-1 were detected with $K_d$ values of 7.36 ± 0.45 μM for Zn$^{2+}$ and 61.68 ± 4.92 μM for colistin (Supplementary Figs. 9a, b). These results suggested that thanatin exhibited approximately 10 times higher affinity to NDM-1 than Zn$^{2+}$.

To further define whether thanatin can inhibit the enzymatic activity of NDM-1, we incubated the purified NDM-1 protein with gradient concentrations of thanatin, and examined the hydrolytic efficacy. The results showed that thanatin inhibited NDM-1 activity in a concentration-dependent manner, with the half-maximum inhibitory concentration (IC$_{50}$) value of 3.21 ± 0.78 μM (Fig. 5d). Classical kinetic plots with varied substrate and inhibitor concentrations were determined to show the manner by which thanatin inhibited NDM-1. The relevant Lineweaver–Burk plot proved that thanatin was a competitive inhibitor for NDM-1, with the inhibition constant ($K_i$) value of 2.84 ± 0.33 μM (Fig. 5e, Supplementary Fig. 10). The kinetic parameters are shown in Supplementary Table 4. These results suggested that thanatin could directly inhibit enzymatic activity of NDM-1 as a competitive inhibitor.

NDM-1 is a dizinc hydrolase with two Zn$^{2+}$ ions in its active site. To directly confirm whether thanatin inhibits NDM-1 by removing Zn$^{2+}$ from NDM-1, we used inducibly coupled plasma–mass spectrometry (ICP-MS) to measure the zinc content in holo-NDM-1 after thanatin treatment. The results confirmed that 2.23 ± 0.28 molar equivalents of zinc were bound to holo-NDM-1 (Fig. 5f). However, only 1.03 ± 0.25 molar equivalents of zinc remain bound to NDM-1 after thanatin treatment (Fig. 5f).
Hence, thanatin released ~1.2 molar equivalents of zinc from holo-NDM-1. In addition, NDM-1 activity inhibited by thanatin was gradually rescued with increasing Zn$^{2+}$ concentrations (Supplementary Fig. 11). Hence, thanatin inhibited NDM-1 reversibly by removing Zn$^{2+}$ from NDM-1. Thanatin, as a cationic peptide, bears a significant positive charge (+6) at physiological pH$^{12}$, implying a repulsive force against metal ions. Although cysteine residues can bind to Zn$^{2+}$$^{17}$, the two cysteines in thanatin have formed a disulfide bridge and cannot function as metal-chelating residues. Therefore, thanatin likely inactivated NDM-1 by displacing the Zn$^{2+}$ ions, rather than by exerting a chelating effect. All the data showed that thanatin inactivated NDM-1 by displacing Zn$^{2+}$ as a competitive inhibitor.

**Thanatin reverses carbapenem resistance in vivo.** The capacity of NDM-1 inhibition suggested that thanatin could potentially protect conventional antibiotics from hydrolysis and restore the antibiotic susceptibility of NDM-1-producing strains. The results of the checkerboard assay showed that, in the presence of sub-MIC thanatin, the antibacterial activity of meropenem toward NDM-1-producing *E. coli* XJ141026 was markedly restored, with the MIC value decreased from 144 μM to 18 μM (Fig. 6a). All fractional inhibitory concentration (FIC) indices were ≤1 for the seven NDM-1-producing strains, indicating that thanatin exerted synergistic or additive effects with imipenem and meropenem (Table 2). The combination of meropenem/imipenem and thanatin showed great bactericidal capacities against NDM-1-producing *E. coli* XJ141026 at concentrations much lower than MICs when monoadministered (Fig. 6b, c). The effects of the combination treatment were determined with the six other NDM-1-producing strains. Consistent results were obtained, indicating that thanatin overcame the antibiotic resistance by inhibiting the hydrolytic activity of NDM-1 (Supplementary Fig. 12). In the systemic infection model, the combination of meropenem and thanatin enhanced the survival rates from 0% for the 0.1 mg/kg thanatin monotherapy group and 30% for the 10 mg/kg meropenem monotherapy group to 79% (Fig. 6d). Bacterial titer data showed that the combination of meropenem and thanatin efficiently restricted the development of sepsis, and the CFUs in the spleen and liver were significantly reduced compared with any other monotherapy groups (Fig. 6e, f).

**Discussion**

Efficient antibiotic treatment must be developed for serious infections caused by NDM-1-producing super-resistant bacteria. Current therapeutic strategies by using polymyxins and tigecycline are problematic due to their high toxicity, poor tissue penetrability, and undesirable pharmacokinetic properties$^{18–20}$. Recent studies have reported that several compounds exert potent activities against NDM-1-producing bacteria$^{21,22}$. However, the situation of restraining infections caused by NDM-1-producing strains is still severe, given high resistance to almost all β-lactam antibiotics, especially carbapenems. Here, we propose thanatin as a promising agent to combat NDM-1-producing bacteria by permeabilization and NDM-1 enzyme inactivation. Thanatin may be potentially used as a therapeutic strategy.

Divalent cations (Mg$^{2+}$ and Ca$^{2+}$) are essential to bridge negative-charged phosphate groups between the LPS molecules, avoiding the accumulation of repulsive forces and maintaining the stability of the bacterial OM$^{14}$. Our results indicated that thanatin causes the release of Ca$^{2+}$ and LPS in a concentration-dependent manner (Fig. 2a, b). The same phenomenon was also observed in vivo, that is, the LPS levels in BALF significantly increased in the mouse pneumonitis model after thanatin.
reported that thanatin targets LptA and LptD in the network of periplasmic protein–protein interactions, leading to the inhibition of LPS transport and OM biogenesis in E. coli. However, they proposed that thanatin has no membrane-permeabilizing effect, which contradicts the present results. We consider that the distinct data raised by Vetterli et al. may be due to the high concentrations of Ca\(^{2+}\) (1 mM) and Mg\(^{2+}\) (0.5 mM) used in the membrane permeabilization assays. According to our results, the antibacterial activity of thanatin obviously decreased under the effect of 1 mM Ca\(^{2+}\); that is, the MIC of thanatin against NDM-1-producing E. coli XJ141026 increased four times (Fig. 3c).

NDM-1 inhibitors, which antagonize multiple subtypes of metallo-\(\beta\)-lactamases and protect \(\beta\)-lactam antibiotics from being hydrolyzed, have been widely studied for synergistic application with \(\beta\)-lactam antibiotics to restore their bactericidal effects\(^{15,25,26}\). The most common mechanism of metallo-\(\beta\)-lactamase inhibitors is metal ion binding\(^{27}\). A recent study showed that the naturally occurring fungal compound aspergil-lomarasmine A inhibits the NDM-1 protease activity by chelating zinc ions from the active site\(^{28}\). Distinct from the direct metal ion binding, our results demonstrated that thanatin acts as an NDM-1 inhibitor by competitively displacing zinc ions. This effect was only observed in thanatin; whereas colistin exhibited almost no effect on NDM-1 activity, indicating that not all cationic antimicrobial peptides can affect enzymolysis (Fig. 5, Supplementary Figs. 8 and 13). This property indicates that thanatin can be used as an NDM-1 inhibitor to effectively restore the susceptibility of NDM-1-producing bacteria to conventional antibiotics (Fig. 7).

### Table 2 FIC indices against NDM-1 clinical isolates

| Strains        | FIC Index | Mem + Tha | Imp + Tha |
|----------------|-----------|-----------|-----------|
| NDM-1 E. coli XJ141015 | 0.625     | 1         |           |
| NDM-1 E. coli XJ141026 | 0.625     | 1         |           |
| NDM-1 E. coli XJ141047 | 0.508     | 0.531     |           |
| NDM-1 K. pneumoniae XJ155017 | 0.750     | 0.750     |           |
| NDM-1 K. pneumoniae XJ155018 | 0.563     | 1         |           |
| NDM-1 K. pneumoniae XJ155019 | 0.516     | 0.313     |           |
| NDM-1 K. pneumoniae XJ155020 | 0.508     | 0.375     |           |

Tha, thanatin; Mem, meropenem; Imp, imipenem.

![Fig. 6](https://example.com/fig6.png) Thanatin rescues the activity of carbapenem. a Microdilution checkerboard analysis showing the combined effect of thanatin (Tha) and meropenem (Mem) against NDM-1-producing E. coli XJ141026. The heat plot showed an average of three technical replicates. b, c Sub-MICs of thanatin reversed the activity of meropenem (b) and imipenem (Imp) (c) resistance in vitro. d NDM-1-producing E. coli XJ141026-infected mice were treated with a single dose of meropenem (10 mg/kg), a combination of meropenem (10 mg/kg) and thanatin (0.1 mg/kg), thanatin alone (0.1 mg/kg), or PBS via intraperitoneal injection (n = 14 per group). e, f Bacterial loads in the spleen (e) and liver (f) of thanatin-treated E. coli XJ141026-infected mice were determined by plating the samples for colony counts 24 h after treatment (n = 6 per group). Data are shown as the mean ± s.e.m. from at least three independent experiments. P-values were determined by one-way ANOVA with Bonferroni’s comparison test (b, c, e, f), or by log-rank test (d). **P < 0.01, ***P < 0.001; #P < 0.01 between 10 mg/kg Mem and Tha + Mem. Source data are provided in Source Data file.

**Fig. 6** Thanatin rescues the activity of carbapenem. a Microdilution checkerboard analysis showing the combined effect of thanatin (Tha) and meropenem (Mem) against NDM-1-producing E. coli XJ141026. The heat plot showed an average of three technical replicates. b, c Sub-MICs of thanatin reversed the activity of meropenem (b) and imipenem (Imp) (c) resistance in vitro. d NDM-1-producing E. coli XJ141026-infected mice were treated with a single dose of meropenem (10 mg/kg), a combination of meropenem (10 mg/kg) and thanatin (0.1 mg/kg), thanatin alone (0.1 mg/kg), or PBS via intraperitoneal injection (n = 14 per group). e, f Bacterial loads in the spleen (e) and liver (f) of thanatin-treated E. coli XJ141026-infected mice were determined by plating the samples for colony counts 24 h after treatment (n = 6 per group). Data are shown as the mean ± s.e.m. from at least three independent experiments. P-values were determined by one-way ANOVA with Bonferroni’s comparison test (b, c, e, f), or by log-rank test (d). **P < 0.01, ***P < 0.001; #P < 0.01 between 10 mg/kg Mem and Tha + Mem. Source data are provided in Source Data file.
The survival of eukaryotes (HUVECs, HPAEpiCs, and mouse neuron cells) was barely affected after incubation with 100 μM thanatin (Supplementary Fig. 7), which is much higher than the antibacterial concentration of thanatin (MIC = 0.4–3.2 μM). Compared with the broadly used polypeptide antibiotic colistin, thanatin exhibits not only excellent antibacterial efficacy but also low cytotoxicity. As such, thanatin is a safe antibacterial agent when applied in vivo and has the potential to combat infections caused by NDM-1-producing bacteria.

In summary, we propose that the antibacterial activity of thanatin is due to dual effects on both the bacterial OM and the NDM-1 enzyme. Thanatin kills NDM-1-producing bacteria and efficiently increases the survival rate of infected mice without conferring obvious toxicity. As such, thanatin is a promising candidate to combat the emergence and dissemination of NDM-1-producing bacteria.

Methods

**Bacterial strains.** E. coli ATCC25922, E. coli ATCC35218, and K. pneumonia ATCC3883 were used as references based on the Chinese National Center for Surveillance of Antimicrobial Resistance. The clinical isolates of E. coli XJ141015, E. coli XJ141026, E. coli XJ141047, K. pneumonia XJ155017, K. pneumonia XJ155018, K. pneumonia XJ155019, and K. pneumonia XJ155020 were obtained from the clinical laboratory of Xijing Hospital (Xi’an, China).

**Screening and identification of NDM-1-producing strains.** Clinical isolate strains were identified and screened by the Phoenix 100 automated bacterial identification system to rapidly detect antimicrobial resistance. Total DNA was extracted by the TIANamp Bacteria DNA Kit according to the manufacturer’s protocol. The presence of bldNDM-1 was confirmed using a diagnostic kit for NDM-1 (Puruikang Bio Inc., Shenzhen, China) based on the Chinese National Center for Surveillance of Antimicrobial Resistance. The clinical isolates of E. coli XJ141015, E. coli XJ141026, E. coli XJ141047, K. pneumonia XJ155017, K. pneumonia XJ155018, K. pneumonia XJ155019, and K. pneumonia XJ155020 were obtained from the clinical laboratory of Xijing Hospital (Xi’an, China).

**Synthesis of thanatin.** Thanatin (GSKKPVPIIYCNRRTGKCQRM) was synthesized by the solid-phase method applying Fmoc (9-fluorenylmethyloxycarbonyl) active ester chemistry. The crude peptide was purified to over 98% chromatographic homogeneity by reverse-phase high-performance liquid chromatography and confirmed by mass spectrometry analysis.

**Expression and purification of NDM-1.** The bldNDM-1 gene was synthesized by Integrated DNA Technologies (Detai Bio-Tech Co., Ltd., Nanjing, China) by deleting the signal peptide gene sequence and introducing a 6 x His gene sequence at the 5’-site. The gene was then cloned into PET30a digested with NdeI and HindIII. The vector was used to encode the NDM-1 enzyme fused to the amino-terminal histidine tag (MHHHHHHPGEPQRTGQMMETGDQRFGLCYVRQ LAPNVWQHTSITLPMGPFGGAVSNGLVRDDGGRVLYVDTAWTDQGAQLN WIRQEQLPLVALAVTHQQKRMGGMLAHAGLTYANALSQNLAPQEG MVAAQHLSLFAANGVVEPATAPNLPGKLVPQPCPGTSDINTVGIDTD AFGGLIKDSSKLGNLGDADTEHYAASARAFGAAFPKASMIVMSHSAPDRA AIHTTARMADKLR). For protein production, PET30a-NDM-1 was transferred into E. coli BL21 (DE3) and the cells were grown in Luria-Bertani (LB) medium containing 50 μg/mL kanamycin. A single colony of E. coli BL21 (DE3)/PET30a-NDM-1 was inoculated into 100 mL of LB culture containing 50 μg/mL kanamycin and grown overnight at 37 °C. The overnight culture was diluted in LB containing 50 μg/mL kanamycin and grown to midlogarithmic phase (OD600 = 0.6). Protein expression was induced by adding 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and 0.5 mM ZnSO4 to the medium. After overnight incubation at 15 °C for 16 h, the cells were harvested by centrifugation at 8000 rpm for 15 min at 4 °C and then resuspended in buffer A (50 mM Tris-HCl buffer, pH = 8.0) containing 300 mM NaCl, 20 mM imidazole, 1% Triton X-100, 1 mM DTT, and 1 mM PMSF. After sonication, the mixture was centrifuged at 12,500 rpm for 15 min at 4 °C. The supernatant was filtered through a 0.45 μm filter (Millipore, USA), loaded onto a Ni-IDA column, and pre-equilibrated with buffer A. The column was washed with buffer A, and the protein was eluted by a linear gradient of imidazole from 50 mM to 500 mM in buffer B. The soluble NDM-1 protein was dialyzed against 2 L of 10 mM PBS (pH = 7.4) overnight at 4 °C and stored at −80 °C. The purified enzyme was verified to be >90% pure as assessed by SDS-PAGE. Protein concentration in the solution was measured with a Bradford protein assay kit, with bovine serum albumin as the standard. Zinc content in the purified NDM-1 was determined using the inductively coupled plasma–mass spectrometry (ICP-MS), ranging from 1.0 to 1.3 molar equivalents of zinc ion.

**Preparation of apo-NDM-1.** The apo form of NDM-1 was prepared by dialysis against EDTA as described by Gonzalez et al. Briefly, apo-NDM-1 was derived from the purified NDM-1 obtained above by the two rounds of dialysis against 100 mM EDTA, 200 mM NaCl, and 200 mM Na2EDTA at pH = 7.4 overnight under stirring. EDTA was removed from the resulting apoenzyme solution by three dialyses against 200 volumes of 10 mM EDTA, 1 M NaCl, pH = 7.4, Chelex 100 and finally three dialyses steps against 200 volumes of 50 mM EDTA, 200 mM NaCl, pH = 7.4, and Chelex 100. All buffer solutions used to prepare the apoenzymes were treated by stirring with Chelex 100 (Bio-Rad). Zinc content in the apoprotein samples was checked using ICP-MS, and apo-NDM-1 contains less than 0.2 molar equivalents of zinc ion.

**Minimum inhibitory concentration (MIC).** MIC values were identified through microdilution in sterilized 96-well polystyrene microtiter plates according to the broth microdilution guideline of the Clinical and Laboratory Standards Institute. The test medium was Mueller–Hinton broth (MHB), and the strain concentrations were adjusted to 5 x 10^5 CFU/mL. After 16 h of incubation at various concentrations of thanatin or other drugs at 37 °C, MIC was defined as the lowest concentration of antibiotic with no visible growth. The MHB medium was supplemented with varying concentrations of MgCl2, CaCl2, DPA, or EDTA to explore the effects of divalent cations (Mg2+, Ca2+) and metal-chelating agents (DPA, EDTA) on the MIC of thanatin against E. coli XJ141026.

**Time-dependent killing.** The time-kill curves for the NDM-1 clinical isolates were identified using drop plate method according to basic microbiological protocol. Bacterial cells were diluted to 1 x 10^8 CFU/mL and incubated with thanatin or ceftazidime for 0, 0.5, 1, 3 or 6 h. At each time point, aliquots of each culture were collected, diluted and plated onto agar plates. After overnight culture, the CFU number was calculated from the colonies growing on the plates, and an untreated inoculum group was used as the negative control.

**Sample preparation for membrane permeability assay.** Thanatin-induced outer and inner membrane permeability was measured as previously described. In brief, 10 mL of LB broth was inoculated with 0.1 mL of saturated E. coli XJ141026 culture and grown at 37 °C overnight. Strains were diluted to 1 x 10^6 CFU/mL, and then thanatin was added to cell cultures to 0.8 μM. An equal volume of sterile PBS was added as the control. The strains were collected, washed, and resuspended in 5 mM HEPES and 5 mM glucose buffer (pH = 7.2) at different time points.

**Outer membrane permeability.** Outer membrane permeability of thanatin was measured by the uptake of 1-N-phenylphthalamine (NPN). The prepared
samples were incubated with NPN (8 μL from a 500 μM stock in acetone) for 30 min at 25 °C. The samples were then transferred to cuvettes. Fluorescence was measured using an F-2500 fluorescence spectrophotometer (Hitachi, Japan) at an excitation wavelength of 350 nm and an emission wavelength of 420 nm.

**Inner membrane permeability.** The inner membrane permeability of thanatin was measured by the uptake of PI19. In brief, 10 μM PI was added to the cells and incubated for 30 min at 25 °C. The fluorescence of the dye was monitored using a fluorescence spectrophotometer at an excitation wavelength of 535 nm and an emission wavelength of 617 nm.

**Scanning electron microscopy.** *E. coli* XJ141026 culture at mid-logarithmic growth-phase was diluted in MHB to 1 × 10⁸ CFU/mL, cultured with 0.8, 1.6 and 3.2 μM thanatin at 230 rpm for 4 h, harvested, and washed. As a control, bacteria were exposed to MHB without the peptide. Some specimens were observed in a scanning electron microscope (Hitachi S-3400N, Japan), and images were recorded.

**Detection of Ca²⁺ and LPS.** The strain *E. coli* XJ141026 was tested in PBS without Ca²⁺ and Mg²⁺. Bacteria were grown to stationary phase, centrifuged, washed and resuspended in PBS (3 × 10⁸ CFU/mL), and incubated with 13 or 26 μM thanatin at 37 °C. Aliquots of thanatin-treated and untreated cultures were obtained at 0, 0.5, 1.5, and 6 h. Then, 50 μL of the culture was used to detect CFUs. The supernatant from the remaining cell suspension was collected by centrifugation and filtered. The filtrate (Millipore) was assessed by a chromogenic limulus amebocyte lysate assay (Xiamen Biodeno Technology, Co., Ltd., China)34. The amount of Ca²⁺ was quantified using an Ample Colorimetric Calcium Quantitation Kit (AAT Bioquest Inc., California, USA), which has a dye that changes color when bound to Ca²⁺. The analyses were conducted in 96-well microtiter plates according to the manufacturer’s protocols.

**Effects of excess Ca²⁺ on bacterial LPS release and CFUs.** *E. coli* XJ141026 was tested in PBS with 0.1, 0.5, and 1 mM Ca²⁺ in the absence or presence of 13 or 26 μM thanatin to explore the effect of Ca²⁺ availability on LPS release from cells treated with thanatin. Bacterial counts and LPS release were detected after 6 h as described above.

**Isothermal titration calorimetry (ITC).** Microcalorimetric measurements of the binding of thanatin or divalent cations (Mg²⁺, Ca²⁺) to LPS were performed on a MicroCal Auto-ITC200 instrument (Malvern Instruments, Malvern, UK)35. *E. coli* (serotype O55:B5, Sigma, USA) was dissolved in 20 mM Tris-HCl (pH = 6.8) to 10 μM PBS (pH = 7.4), vortexed vigorously for 15 min, and sonicated for 15 min at 60 °C. The LPS solution was sonicated for 5 min prior to use. Thanatin was dissolved in Tris-HCl (pH = 6.8) and titrated into LPS in Tris-HCl (pH = 6.8). Divalent cations (Mg²⁺, Ca²⁺) were dissolved in PBS (pH = 7.4) and titrated into LPS in PBS (pH = 7.4). All samples were degassed for 10 min in a sonication bath before the experiments. These experiments were performed at 25 °C. The generated peaks were integrated using Origin 7.0 software. The errors for all the reported thermodynamic parameters were estimated through Monte Carlo simulation with the standard errors of three experiments.

**Detection of NDM-1 protein levels and hydrolytic activity.** An overnight culture of *E. coli* XJ141026 was diluted to 1:2 in LB and incubated at 37 °C with 0.8%, 1.6, and 3.2 μM thanatin or colistin under shaking at 250 rpm for 6 or 12 h. At given intervals, the culture supernatant was collected by centrifugation at 12,000 rpm and 4 °C for 20 min and filtered through 0.22 μm filters to eliminate bacteria. NDM-1 level in the filtered supernatant was measured using a specific ELISA kit (Shanghai Enzyme-linked Biotechnology Co., Ltd., China) and western blot analysis. Imipenem hydrolysis in the filtered supernatant at 6 h was monitored using a Biotech powerwave HT microplate spectrophotometer at 30 °C by determining the changes in absorbance at 300 nm, with a final substrate concentration of 100 μM, imipenem of 1 mM, and LPS concentration obtained from the background. The IC₅₀ value was determined using the NDM-1 ELISA kit (Shanghai Enzyme-linked Biotechnology Co., Ltd., China) to LPS at 230 rpm for 4 h, harvested, and washed. As a control, bacteria were exposed to MHB without the peptide. Some specimens were observed in a scanning electron microscope (Hitachi S-3400N, Japan), and images were recorded.

**NDM-1 inhibition assays.** IC₅₀ value and Kᵢ were detected to evaluate the inhibitory effect of thanatin. Thanatin was dissolved in 50 mM HEPES (pH = 6.8) containing 0.05% Tween-20 to a final concentration of 800 μM and incubated in the same buffer. The purified NDM-1 protein was dissolved in 50 mM HEPES (pH = 7.4) containing 0.05% Tween-20 and supplemented with 10 μM ZnSO₄, pre-incubated with different concentrations of thanatin for 20 min at 30 °C. The assay was initiated by adding imipenem to the mixture of NDM-1 and thanatin, with a final enzyme concentration of 1 nM, imipenem of 100 μM and 12 different concentrations of thanatin. The change in absorbance at 300 nm was monitored for 30 min in 96-well plates at 30 °C. The initial rate of reaction for each inhibitor concentration was calculated from the slope of the initial linear phase of the respective time course. The IC₅₀ value was obtained by plotting the residual enzyme activity against inhibitor concentration (log₁₀). Kᵢ was obtained by nonlinear fitting of the initial rates (Vₐ₀) of the hydrolysis of imipenem (100, 200, 400, 800, 1600 μM) by 1 nM NDM-1 in the absence and presence of three concentrations of thanatin. The best fits were obtained with the competitive inhibition model by using the equation:

\[
V_0 = \frac{V_{max} \times [S]}{K_m + [S] + K_i} \times [I] + \frac{V_{max}}{K_m} \times [I], \quad \text{and} \quad [S] \text{in the equation correspond to Michaelis–Menten constant, thanatin concentration, and imipenem concentration, respectively. The kinetic parameters } K_m, V_{max}, K_i \text{ and } V_{max}/K_m \text{ were calculated by fitting the data into the double reciprocal Lineweaver–Burk plots. GraphPad 5.0 was used for data analysis.}
\]

**Zn²⁺ restoration assays.** Purified NDM-1 (4 nM) supplemented with 10 μM ZnSO₄ was mixed with thanatin (200 μM) in 11:1 volume ratio. After incubating for 20 min at 30 °C, 50 μM of the mixture was added to the 96-well plate. The total volume was adjusted to 100 μL with the following final concentrations: 1 nM NDM-1, 50 μM thanatin, 100 μM imipenem and ZnSO₄ ranging from 0.1 μM to 800 μM. The absorbance at 300 nm was monitored for 30 min at 30 °C. Percent residual activity was calculated from the thanatin-free control.

**Microscale thermophoresis (MST).** The Kᵢ values of the binding of NDM-1 to Zn²⁺, thanatin and colistin were measured using a Monolith NT.115 Pico (Nanotemper Technologies GmbH, Munich, Germany)36. NDM-1 carrying a histidine-tag (His-tag) was labeled with the RED-tris-NTA second-generation dye for 30 min at room temperature in the dark according to the manufacturer’s instructions (Monolith His-tag Labeling Kit RED-tris-NTA 2nd Generation, Nanotemper Technologies GmbH). Zn²⁺, thanatin, and colistin solutions were separately diluted in the reaction buffer (50 mM HEPES buffer [pH = 7.4] containing 0.05% Tween-20 for Zn²⁺ and colistin; 50 mM HEPES [pH = 6.8] containing 0.05% Tween-20 for thanatin). Then, 100 nM labeled NDM-1 protein was added to the serial dilution of the compound in a 1:1 volume ratio. After incubation for 30 min at room temperature, the samples were examined with Monolith NT.115 in Premium Capillaries (MO-K025) at medium MST power and 5% LED excitation power. Kᵢ values were determined using the Monolignt Affinity Analysis Kᵢ fit from triplicate experiments.

**Preparation of holo-NDM-1 and ICP-MS assay.** To prepare holo-NDM-1, wild-type NDM-1 was incubated with 2.5 nM Zn²⁺ in the ICP-MS buffer (50 mM HEPES, 200 mM NaCl, pH = 7.4) for 1 h on ice. The reconstituted holo-NDM-1 was dialyzed (10 kDa MWCO) overnight at 4 °C against 100 volumes of Chelex-treated ICP-MS buffer containing 0.05% Tween-20 and desalted in the same buffer by using 7 kDa MWCO Zeba™ Spin Desalting Columns (Thermo Fisher Scientific) to remove excess Zn²⁺. Following the exchange, the holo-NDM-1 was diluted to 4 μM and incubated with 0.2, 0, 40, and 80 μM thanatin for 3 h at room temperature with gentle shaking. The thanatin-treated holo-NDM-1 was buffer-exchanged again to remove any unbound Zn²⁺ and thanatin as described above. The final protein concentration was determined using the NDM-1 ELISA kit (Shanghai Enzyme-linked Biotechnology Co., Ltd., China). The final protein was diluted to 1 μM and digested in 5% nitric acid at 80 °C for 1 h. The digested samples were measured with a Perkin Elmer NexION® 350D ICP-MS38. The concentrations of Zn²⁺ were calculated according to the calibration curve, and data were corrected by subtracting the background obtained from the background control buffer. Finally, the molar equivalents of Zn²⁺ were calculated from the ratio of Zn²⁺ concentration to the enzyme concentration.
Fractional inhibitory concentration (FIC). Synergy in vitro was assessed by checkerboard assays. The plates were set up with serial doubling dilutions of thanatin and meropenem or imipenem at various concentrations. Following incubation, the synergistic/additive effect was determined by calculating the FIC indices (FICI) according to the formula: FICI = (MIC of A in combination/MIC of A) + (MIC of B in combination/MIC of B). The synergy or additive was defined according to standard criteria (FICI ≤ 0.5 was defined as synergistic; 0.5 < FICI ≤ 1 was defined as additive; 1 < FICI ≤ 4 was defined as indifference; FICI > 4 was defined as antagonism).

The kill curves were determined as mentioned above to investigate the bactericidal activity of the combination treatment. Bacterial cells were diluted to 1 × 10^6 CFU/ml and incubated with thanatin, carabenepem or their combination for 16 h. CFUs were counted.

Cytotoxicity. HUVECs (ATCC-CRL1730) were cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 units/mL). HA/HPaEPCs (ScienCell Research Lab., Catalog#2320, San Diego, CA) were incubated in alveolar epithelial cell medium (AEPsCM, ScienCell Research Lab., Catalog#23021). HUVECs and HA/HPaEPCs were seeded into 96-well plates at 5 × 10^3 cells/well for 24 h. The cells were washed twice with PBS and once with the corresponding serum-free culture medium. The cells were treated with a range of concentrations of thanatin or colistin in the serum-free culture medium for 24 h. Cytotoxicity was analyzed using Cell Counting Kit (CCK-8) (Dojindo, Kumamoto, Japan).

Mouse studies. Male BALB/c mice aged 8–10 weeks and weighing 18–22 g were used. The experimental and animal care procedures were approved by the animal care and use committee of the Fourth Military Medical University.

Mouse pneumonia model. The mice were anesthetized with 10 mg/kg pentobarbital via intraperitoneal injection at a dose of 60 mg/kg and intranasally infected with 1 × 10^9 CFU E. coli XJ141026 or K. pneumoniae XJJ5017 in 0.1 or 0.5 mL of MHB. After bacterial challenge, the mice were treated with a 1, 3, 6 or mg/kg thanatin at 1 and 6 h. Six mice in each group were anesthetized with 10 mg/mL pentobarbital via intraperitoneal injection at a dose of 60 mg/kg to assess bacterial clearance. Afterward, 100 μL of the blood samples were collected from retro-orbital sinus after bacterial challenge for 24 h. The lungs, livers, and spleens were harvested aseptically from each sacrificed animal. The organs were weighed and homogenized in sterile saline solution. The homogenates were plated onto agar plates at appropriate dilutions concentrations. Colonies were counted after 18 h of incubation at 37 °C. Colony counts in the tissues and blood were expressed as CFU/g. The survival of 10 mice in each group was monitored for 7 d after infection. Cumulative survival rate was determined.

BALF was collected after thanatin treatment at 1 and 6 h and filtered through a 0.22 μm filter. The bacterial numbers and LPS levels were measured as described above.

Mouse sepsis model. A sepsis model was established through an intraperitoneal administration of 4 × 10^9 CFU E. coli XJJ141206 in 0.1 mL of MHB. After bacterial challenge, the mice were treated with a 1, 3, 6 mg/kg thanatin at 1 and 6 h. Six mice in each group were anesthetized with 10 mg/mL pentobarbital via intraperitoneal injection at a dose of 60 mg/kg to assess bacterial clearance. Afterward, 100 μL of the blood samples were collected from retro-orbital sinus after bacterial challenge for 24 h. The lungs, livers, and spleens were harvested aseptically from each sacrificed animal. The organs were weighed and homogenized in sterile saline solution. The homogenates were plated onto agar plates at appropriate dilutions concentrations. Colonies were counted after 18 h of incubation at 37 °C. Colony counts in the tissues and blood were expressed as CFU/g. The survival of 10 mice in each group was monitored for 7 days after infection. Cumulative percentage survival was calculated. Parts of the lung, liver, and spleen were harvested, washed with sterile PBS, and fixed in 10% formaldehyde for 24 h. Their morphologies were observed using H&E staining.

Synergism of thanatin and meropenem in the sepsis model. BALB/c mice were infected intraperitoneally with 8 × 10^9 CFU of E. coli XJ141026 in 0.1 mL of MHB. The mice were treated with 10 mg/kg meropenem, 0.1 mg/kg thanatin, or their combination at 1 h post challenge. The model group was intraperitoneally injected with an equivalent volume of PBS. Six mice in each group were sacrificed after bacterial challenge for 24 h to assess bacterial clearance in the spleens and livers. In addition, the survival rates were detected as described above.

Statistical analysis. The results are expressed as means ± s.e.m. Unpaired two-tailed t-tests, one-way ANOVA, two-way ANOVA or log-rank test were used for statistical evaluations. A probability (P) value of 0.05 was considered indicative of statistical significance.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The source data underlying Figs. 1a–d, 2a, 3a–d, 4, 5, and 6–f, and Supplementary Figs. 1, 2a–d, 4a, b, 8a–6, 9, 10, 11, and 12 are provided in the Source Data file. The original data for each processed plot and figure are also available in the Source Data file. All other data that support the findings of this study are available from the corresponding author upon request.

Received: 24 August 2018 Accepted: 16 July 2019
Published online: 06 August 2019

References

1. Johnson, A. P. & Woodford, N. Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. J. Med. Microbiol. 62, 499–513 (2013).
2. Kumarasamy, K. K. et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597–602 (2010).
3. Rolain, J. M., Parola, P. & Cornaglia, G. New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia? Clin. Microbiol. Infect. 16, 1699–1701 (2010).
4. Khan, A. U., Maryam, L. & Zarrilli, R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-beta-lactamase (NDM): a threat to public health. BMC Microbiol. 17, 101 (2017).
5. Zhong, L. L. et al. Coproduction of MCR-1 and NDM-1 by colistin-resistant Escherichia coli isolated from a healthy individual. Antimicrob. Agents Chemother. 61, e01962–17 (2017).
6. Delgado-Blas, J., Ovejero, C. M., Abadia-Patio, L. & Gonzalez-Zorn, B. Coexistence of mcr-1 and blaNDM-1 in Escherichia coli from Venezuela. Antimicrob. Agents Chemother. 60, 6356–6358 (2016).
7. Stewart, A. C. et al. Clinical Variants of New Delhi metallo-beta-lactamase are evolving to overcome zinc scarcity. ACS Infect. Dis. 3, 927–940 (2017).
8. Brem, J. et al. Structural basis of metallo-beta-lactamase-serine-beta-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 12, 7408 (2016).
9. Gonzalez, L. J. et al. Membrane anchoring stabilizes and favors secretion of New Delhi metallo-beta-lactamase. Nat. Chem. Biol. 12, 516–522 (2016).
10. Brophy, M. B., Hayden, J. A. & Nolan, E. M. Calcium ion gradients modulate the zinc affinity and antibacterial activity of human calprotectin. J. Am. Chem. Soc. 134, 18089–18100 (2012).
11. Ubina, B. D. et al. Metal ionization and inhibition of bacterial growth in tissue abscesses. Science 319, 962–965 (2008).
12. Fehlbaum, P. et al. Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc. Natl Acad. Sci. USA 93, 1221–1225 (1996).
13. Hou, Z. et al. Underlying mechanism of in vivo and in vitro activity of C-terminal-amidated thanatin against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli. J. Infect. Dis. 203, 273–282 (2011).
14. Clifton, L. A. et al. Effect of divalent cation removal on the structure of gram-negative bacterial outer membrane models. Langmuir 31, 404–412 (2015).
15. Groundwater, P. W. et al. New Delhi metallo-beta-lactamase-1: structure, inhibitors and detection of producers. Future Med. Chem. 8, 993–1012 (2016).
16. Gonzalez, J. M. et al. Metallo-beta-lactamases withstand low Zn(II) conditions by tuning metal-ligand interactions. Nat. Chem. Biol. 8, 698–700 (2012).
17. Giles, N. M. et al. Metal and redox modulation of cysteine protein function. Chem. Biol. 10, 677–693 (2003).
18. Koch-Weser, J. et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72, 857–868 (1970).
19. Landman, D., Georgescu, C., Martin, D. A. & Quale, J. Polymyxins revisited. Expert Opin. Pharmacother. 19, 979–992 (2018).
20. Zhang, Y., Lin, X. & Bush, K. I. In vitro susceptibility of beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J. Antibiot. (Tokyo) 69, 600–604 (2016).
22. Zhang, Y., Kashikar, A. & Bush, K. In vitro activity of plazomicin against beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). J. Antimicrob. Chemother. 72, 2792–2795 (2017).
23. Sinha, S., Zheng, L., Mu, Y., Ng, W. J. & Bhattacharjya, S. Structure and interactions of a host defense antimicrobial peptide thanatin in lipopolysaccharide micelles reveal mechanism of bacterial cell agglutination. Sci. Rep. 7, 17795 (2017).
24. Vetterli, S. U. et al. Thanatin targets the intermembrane protein complex required for lipopolysaccharide transport in Escherichia coli. Sci. Adv. 4, eaau2634 (2018).
25. Lienard, B. M. et al. Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiolis. Org. Biomol. Chem. 6, 2282–2294 (2008).
26. Wang, R. et al. Bismuth antimicrobial drugs serve as broad-spectrum metallo-beta-lactamase inhibitors. Nat. Commun. 9, 439 (2018).
27. Ju, L. C., Cheng, Z., Fast, W., Bonomo, R. A. & Crowder, M. W. The continuing challenge of metallo-beta-lactamase inhibition: mechanism matters. Trends Pharmacol. Sci. 39, 635–647 (2018).
28. King, A. M. et al. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510, 503–506 (2014).
29. Ma, R. et al. The Disulfide Bond of the Peptide Thanatin Is Dispensable for Its Antimicrobial Activity In Vivo and In Vitro. Antimicrob. Agents Chemother. 60, 4283–4289 (2016).
30. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Clinical Laboratory Standards Institute, M07-A09, (2012).
31. Herigstad, B., Hamilton, M. & Heersink, J. How to optimize the drop plate method for enumerating bacteria. J. Microbiol. Methods 44, 121–129 (2001).
32. Hancock, R. E., Farmer, S. W., Li, Z. S. & Poole, K. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob. Agents Chemother. 35, 1309–1314 (1991).
33. Yarlagadda, V., Akkapeddi, P., Manjunath, G. B. & Haldar, J. Membrane active vancomycin analogues: a strategy to combat bacterial resistance. J. Med. Chem. 57, 4558–4568 (2014).
34. Lindsay, G. K., Roslansky, P. F. & Novitsky, T. J. Single-step, chromogenic Limulus amebocyte lysate assay for endotoxin. J. Clin. Microbiol. 27, 947–951 (1989).
35. Khan, A. U., Ali, A., Danishuddin, Srivistava, G. & Sharma, A. Potential inhibitors designed against NDM-1 type metallo-beta-lactamas: an attempt to enhance efficacies of antibiotics against multi-drug-resistant bacteria. Sci. Rep. 7, 9207 (2017).
36. Bartoschik, T. et al. Near-native, site-specific purification and protein-labeling protocol for quantitative protein interaction analysis by MicroScale Thermophoresis. Sci. Rep. 8, 4977 (2018).
37. Lata, S., Gavutis, M., Tampe, R. & Pipher, J. Specific and stable fluorescence labeling of histidine-tagged proteins for dissecting multi-protein complex formation. J. Am. Chem. Soc. 128, 2365–2372 (2006).
38. Chan, A. N. et al. Role for dithiopyrrolylones in disrupting bacterial metal homeostasis. Proc. Natl Acad. Sci. USA 114, 2717–2722 (2017).

39. Doern, C. D. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J. Clin. Microbiol. 52, 4124–4128 (2014).

Acknowledgements
We thank Xiaoxi Xu and Shan Zhou for providing us with NDM-1 strains from the Department of Clinical Laboratory Medicine of Xijing Hospital. This work was supported by grants from the National Natural Science Foundation of China (nos. 81673477, 81471997, and 81001460).

Author contributions
Z.H., B.M., and X.X.L. designed the experiments; Y.Z. and M.Z.W. accomplished the expression and purification of NDM-1 protein; B.M., L.S.L., M.Z.W., and X.Y.X. performed the experiments; Y.H. and M.K.I. analyzed the data; C.F., Z.H., and B.M. wrote the manuscript. All authors reviewed the manuscript.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-019-11503-3.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Peer review information: Nature Communications thanks Alejandro Vila and other anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.